In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany, and Japan. These therapies are projected to capture more than 90% of market share in this region by 2030 due to their potential to improve patient convenience and...
During insulin’s first century, treatments and resources for people with diabetes have steadily progressed. So, too, have relationships between the patient and the provider. A recent Endocrine Society-hosted roundtable highlighted this vital connection and how it has evolved through the decades. Leonard Thompson was 14 years old in 1922, and he was dying of type...New App Helps Parents Identify Treatable Childhood Growth Disorders Earlier
A mobile phone app can place the accurate measurement of children’s height in the hands of parents and caregivers. Preliminary data presented at the Society for Endocrinology annual conference in Edinburgh suggests that the app could reliably identify treatable growth disorders much earlier, with significant improvements in child health. Childhood growth is a strong indicator...
Baseline IGF-1 and Stimulated GH Can Predict Pediatric GHD Severity, Response to Treatment
Baseline insulin-like growth factor-1 (IGF-1) and stimulated peak growth hormone response can serve as predictors for how severe growth hormone deficiency is in pediatric patients as well as how these patients will respond to different treatments, according to a study recently published in the Journal of the Endocrine Society. Researchers led by Michael O. Thorner,...
The investigational long-acting, once-weekly prodrug lonapegsomatropin (TransCon hGH) may be more beneficial to treatment-naïve pediatric patients with growth hormone deficiency (GHD) than daily somatropin of equivalent weekly dose, according to a paper recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Aimee D. Shu, MD, of Ascendis Pharma (who funded the...
Found in Translation: New Diabetes Guides Increase Accessibility for All
As high-tech innovations improve diabetes management, patients in underserved communities can often lag behind. Addressing the need for more education, Anne Peters, MD, spearheaded a new project that has created easy-to-read guides that make diabetes education easily understood by underserved populations. Type 1 diabetes is a challenging condition for any patient to manage, but it...Mexican Revelation: The Health Disparities of Fatty Liver Disease in Hispanics
Hepatic steatosis — more commonly known as fatty liver disease — appears to have a disproportional effect on Hispanic Americans, with Mexican Americans at an even higher risk. A better understanding of these risk factors is crucial to creating better individualized care protocols for these patients. In 2018, the National Institute of Minority Health and...
